News & Press

GeNeuro SA obtains the opening of debt-restructuring proceedings

Geneva, Switzerland, 30 September 2024 – 7:00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – G NRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases, announces that the Geneva Court of First Instance has approved its application for a debt-restructuring moratorium dated July 15, 2024, aimed at restructuring its debts and finding solutions for the continuity of its activities in the interests of all stakeholders.

New data presented at the ECTRIMS 2024 Congress in Copenhagen shows that Temelimab rescues the neurodegenerative effects of HERV-W in an MS model

Geneva, Switzerland, September 19, 2024 – 6:30 pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on addressing the factors driving the progression of neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), today announced that new findings on the anti-neurodegenerative effect of Temelimab in an MS model were presented as a poster at the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) 2024 Congress in Copenhagen, Denmark. The presentation was delivered by Dr. Joel Gruchot from Prof. Patrick Küry’s group at the Department of Neurology, Heinrich-Heine-University Düsseldorf, Germany, in collaboration with the Department of Neurology at the University of Bern, Switzerland, and the Institute of Pharmacology and Toxicology, University of Zürich, Switzerland.

GeNeuro announces that it submits a request for a debt moratorium to the Geneva Court of First Instance

Geneva, Switzerland, July 15, 2024 – 7:00 am CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO), a biopharmaceutical company developing new treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or COVID-Long), announces that it will submit today to the Geneva Court of First Instance a request for a debt moratorium to restructure its debts and find solutions for the continuity of its activities in the interests of all stakeholders

GeNeuro announces the results of the GNC-501 in post-COVID-19 syndrome

Geneva, Switzerland, June 28, 2024 – 7:00 am CEST – The GNC-501 clinical trial is a Phase 2 study in patients suffering from post-COVID-19 neuropsychiatric syndromes, testing temelimab against placebo. The study enrolled over 200 patients in Switzerland, Spain and Italy who had tested positive for HERV-W ENV. The top-line results from this study show that treated patients had no clinically meaningful improvement compared to placebo on the primary endpoint measuring the improvement of fatigue with the PROMIS SF7a test. The majority of secondary endpoints did not show an effect either. The treatment was very well tolerated and safe, consistent with previous clinical trials in other indications.

GeNeuro Announces Approval of all Resolutions Proposed at 12 June 2024 Annual General Meeting

GeNeuro Announces Approval of all Resolutions
Proposed at 2024 Annual General Meeting

Geneva, Switzerland, June 14, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Annual General Meeting (AGM) of 12 June 2024.

/https://geneuro.ch/wp-content/uploads/GeNeuro_AGM_14062024-EN.pdf

GeNeuro Announces Last Patient Last Visit in its Post-COVID Trial and Confirms Top-Line Results by End of June 2024

Geneva, Switzerland, May 16, 2024 – 8.00 am CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing therapies for patients with neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post- Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced that the last patient enrolled in the GNC-501 trial of temelimab against post-COVID has now completed the study.

GeNeuro publishes its 2023 Universal Registration Document

Geneva, Switzerland, May 2, 2024 – 6:00pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing novel treatments for neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe consequences of COVID- 19, (PASC, post-COVID or Long-COVID), publishes its 2023 Universal Registration Document, in English, which has been filed on April 30, 2024 with the “Autorité des Marchés Financiers (AMF)”.

GeNeuro Reports 2023 Full-Year Results and Provides Corporate Update

Geneva, Switzerland, April 30, 2024 – 6.30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, long COVID or post-COVID), reported today its full-year results for the year ended December 31, 2023, and provided a corporate update.

GeNeuro Announces Approval of all Resolutions Proposed at March 18, 2024, Extraordinary General Meeting

Geneva, Switzerland, March 20, 2024 – 6:30pm CEST – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company developing treatments for neurodegenerative and autoimmune diseases, such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the severe neuropsychiatric consequences of COVID-19 (post-COVID or Long-COVID), today announced that its shareholders have approved all resolutions proposed at its Extraordinary General Meeting (EGM) of March 18, 2024.

https://geneuro.ch/data/news/GeNeuro_EGM-20032024-EN-v2.pdf

GeNeuro announces the availability of a prospectus for the listing of new shares on Euronext Paris

Geneva, Switzerland, February 2, 2024 – 20:00 CEST – GeNeuro (Euronext Paris : CH0308403085 – GNRO) (the “Company”), a biopharmaceutical company focused on halting the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and the post-acute sequelae of COVID-19 (PASC, COVID long or post-COVID), announces that on February 2, 2024, the Autorité des marchés financiers (the “AMF”) approved an admission prospectus under number 24-016 (the “Prospectus”) in connection with the admission to trading on the regulated market of Euronext Paris of 4.666,901 new ordinary bearer shares of the Company issued following a capital increase of 5 million euros with cancellation of preferential subscription rights carried out as part of (i) an international private placement reserved for specialized and strategic investors of 4.666,901 new ordinary bearer shares (the “International Private Placement”) and (ii) a separate public offering to retail investors via the PrimaryBid platform in France of 95,004 new ordinary bearer shares (together with the International Private Placement, the “Offering”).

Français: https://geneuro.ch/data/news/Geneuro-CP-norme-de-mise-a-dispo-prospectus-02.02.2024.pdf

GeNeuro announces a successful €5 million private placement

Geneva, Switzerland,  February 2, 2024 – 08:00 CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announced the successful completion of a €5 million capital increase with cancellation of the preferential subscription rights through an international private placement reserved for specialized or strategic investors of (the “Private Placement”) 4,666,901 new ordinary bearer shares of GeNeuro and through a public offering for retail investors in France via the PrimaryBid platform (the “PrimaryBid Offer”, and together with the Private Placement, the “Offering”) of 95,004 new ordinary bearer shares of GeNeuro. All new ordinary shares have a par value of CHF 0.05 each (the “New Shares”).

https://geneuro.ch/data/news/PR-GeNeuro-Closes-Financing-ENG-02.02.2024.pdf

GeNeuro launches an offering with a commitment to subscribe by existing shareholders and announces its cash position at December 31, 2023

Geneva, Switzerland, February 1, 2024– 5.45pm CET – GeNeuro (Euronext Paris: CH0308403085 – GNRO), a biopharmaceutical company focused on stopping the progression of neurodegenerative and autoimmune diseases such as multiple sclerosis (MS), amyotrophic lateral sclerosis (ALS) and Post-Acute Sequelae of COVID-19 (PASC, long-COVID or post-COVID), today announces the launch of a private placement of ordinary shares to be issued by the Company, in connection with a share capital increase without preferential subscription rights of an indicative amount of €5 million by way of a private placement reserved to certain qualified investors, with an accelerated book-building; the offering will also include a public offering for retail investors, in France only through the PrimaryBid platform. The Company also announces its 2023 year-end cash position.

https://geneuro.ch/data/news/PR-GeNeuro-Announces-YE-2023-Cash-and-Launches-Financing-eng.pdf